Syndax Pharmaceuticals, Inc. (SNDX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 99.68M USD | Liabilities, Current |
| Cash and equivalents | 336.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 33.16M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $99.68M | $336.48M | (m) | (m) | $33.16M | (m) |
| 2026-03-31 | (m) | $86.17M | $130.89M | (m) | (m) | $34.95M | (m) |
| 2025-12-31 | (m) | $120.12M | $134.93M | (m) | $38.00M | $32.75M | (m) |
| 2025-09-30 | (m) | $114.19M | $116.81M | (m) | (m) | $25.00M | (m) |
| 2025-06-30 | (m) | $112.99M | $108.64M | (m) | (m) | $17.70M | (m) |
| 2025-03-31 | (m) | $94.55M | $153.99M | (m) | (m) | $4.66M | (m) |
| 2024-12-31 | (m) | $103.55M | $154.08M | (m) | $7.60M | $366.00K | (m) |
| 2024-09-30 | (m) | $59.38M | $133.02M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $42.47M | $105.40M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $50.80M | $114.61M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $58.10M | $295.39M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $39.17M | $94.55M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $30.17M | $97.28M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $23.72M | $57.52M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $29.07M | $74.36M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $20.80M | $71.38M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $30.93M | $120.24M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $30.55M | $188.77M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $20.68M | $221.97M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $28.71M | $71.43M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $24.29M | $68.04M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $24.57M | $64.39M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $18.87M | $115.24M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $15.16M | $56.36M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $12.47M | $53.61M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $18.79M | $44.63M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $18.37M | $24.61M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $18.29M | $30.58M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $17.49M | $26.67M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $15.66M | $58.12M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $16.11M | $33.77M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $17.02M | $26.70M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $19.30M | $32.20M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $16.91M | $27.98M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $15.80M | $35.17M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $14.21M | $20.73M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.51M | $22.99M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $10.99M | $22.36M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $10.37M | $23.84M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $9.15M | $12.75M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.55M | $14.44M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.04M | $23.19M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $4.85M | $23.18M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $54.21M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $6.75M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $9.28M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $10.01M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $10.10M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |